Singapore, March 3 -- Callio Therapeutics, a Singapore and US-based biotechnology startup focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, has announced its launch with the closing of a$187 millionSeries A financing round.

This financing was led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The newly formed company, with headquarters inSeattleandSingapore, intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a sec...